National Wealth Management Group LLC Makes New $755,000 Investment in IQVIA Holdings Inc. $IQV

National Wealth Management Group LLC bought a new position in IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, HoldingsChannel.com reports. The firm bought 3,349 shares of the medical research company’s stock, valued at approximately $755,000.

Other large investors also recently made changes to their positions in the company. Boston Partners purchased a new position in IQVIA during the third quarter worth about $676,698,000. Norges Bank bought a new position in shares of IQVIA during the 2nd quarter worth approximately $270,160,000. AQR Capital Management LLC boosted its stake in shares of IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after buying an additional 879,701 shares during the last quarter. Qube Research & Technologies Ltd boosted its stake in shares of IQVIA by 86.0% in the 2nd quarter. Qube Research & Technologies Ltd now owns 1,250,174 shares of the medical research company’s stock worth $197,015,000 after buying an additional 578,035 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of IQVIA by 193.1% in the second quarter. Arrowstreet Capital Limited Partnership now owns 848,771 shares of the medical research company’s stock valued at $133,758,000 after acquiring an additional 559,190 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Evercore reissued an “outperform” rating and issued a $225.00 price objective on shares of IQVIA in a research report on Thursday, February 5th. Jefferies Financial Group cut their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 6th. BMO Capital Markets set a $250.00 price target on shares of IQVIA in a research report on Friday, February 6th. Royal Bank Of Canada started coverage on shares of IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective for the company. Finally, UBS Group dropped their target price on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $229.13.

IQVIA Stock Down 0.3%

IQV stock opened at $165.54 on Thursday. The stock has a fifty day moving average of $189.63 and a 200-day moving average of $205.63. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The company has a market capitalization of $28.09 billion, a price-to-earnings ratio of 21.06, a PEG ratio of 1.60 and a beta of 1.39. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.